Moreover, Xu et al. further demonstrated that ccRCC patients undergoing anti-PD-1/PD-L1 therapy exhibited improved survival and response rates when intratumoral TLSs and SFL-TLSs were present 73. Here, PDCD1 is linked to nonpapillary renal cell carcinoma.